Jiang Danqing Chang

US Patent:

7582478, Sep 1, 2009

Filed:

Jan 22, 2004

Appl. No.:

10/763037

Inventors:

Robert J. Schwartz - Houston TX, US
Lei Wei - Pearland TX, US
Jiang Chang - Houston TX, US
Mark Entman - Houston TX, US

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

C12N 5/00
C12N 5/02
A61K 48/00
A61K 38/30

US Classification:

435325, 514 12, 424 932, 424 936

Abstract:

The present invention is directed to the cleavage of serum response factor as it relates to cardiac disease. In specific embodiments, failing cardiac tissue is diagnosed in tissues comprising elevated cleavage of serum response factor. In further specific embodiments, heart failure is associated with cardiac myocyte apoptosis as a result of an increase in cleaved serum response factor, particularly by caspases.

US Patent:

20060142193, Jun 29, 2006

Filed:

Nov 9, 2005

Appl. No.:

11/270653

Inventors:

Lei Wei - Fishers IN, US
Robert Schwartz - Houston TX, US
Jiang Chang - Houston TX, US
Mark Entman - Houston TX, US

Assignee:

BAYLOR COLLEGE OF MEDICINE - Houston TX

International Classification:

A61K 38/17
A61K 48/00

US Classification:

514012000, 514044000

Abstract:

The present invention is directed to the treatment and/or prevention of disease as it relates to Rho kinase. In specific embodiments, disease is treated and/or prevented through the administration of an agent that selectively inhibits ROCK1. In specific embodiments, it inhibits ROCK1 and not ROCK2. In other specific embodiments, the disease is cardiac disease.

US Patent:

20090293139, Nov 26, 2009

Filed:

Apr 3, 2009

Appl. No.:

12/418403

Inventors:

Jiang Chang - Houston TX, US
Robert J. Schwartz - Houston TX, US
Viraj R. Shah - Houston TX, US

Assignee:

The Texas A&M University System Agency State of Texas - College Station TX

International Classification:

C12N 15/00
C12N 15/63

US Classification:

800 22, 4353201

Abstract:

A double-inducible system for expressing a transgene, preferably comprising an RU486-inducible system integrated with a CID-inducible system. The invention further comprises a gene expression system for use in in vitro cell culture studies, and a gene expression expression system for use in engineering modified bigenic mice.